Cambridge, UK, 15 April 2021 – Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.
This author has yet to write their bio.
Meanwhile lets just say that we are proud resilience contributed a whooping 15 entries.
London, UK, 16 March 2021 – Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has been awarded a UK Biomedical Catalyst early award grant from Innovate UK to support the development of a novel disease-modifying antibody therapy for Huntington’s disease (HD). The grant will support Alchemab in its pioneering collaboration with Medicines Discovery Catapult.
5 November 2020 – The operating landscape has changed remarkably for many life science and technology businesses in the Cambridge Cluster since the March 23 lockdown and subsequent restrictions affecting lifestyle and working practices. Read full article
1 November 2020 – The UK BIA Antibody Taskforce, a UK consortium developing antibodies for treating COVID-19, has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody cocktail. Read full article
29 October 2020 – The UK BIA Antibody Taskforce, a leading UK consortium developing antibodies for treating COVID-19 has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody “cocktail”. The Taskforce developed an accelerated and rigorous multifaceted approach to create a pool […]
29 September 2020 – Alchemab, a UK biotech company focused on harnessing the power of adaptive immune systems to cure disease, announced a strategic partnership with the Alberta Machine Intelligence Institute (Amii) to accelerate its adoption of artificial intelligence. Read full article
11 September 2020 – OBN Award Finalists Read full article
20 July 2020 – British Patient Capital provided a $65 million anchor investment for SV7 Impact Medicine Fund, which will aim to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases. Read full article
20 July 2020 – British Patient Capital has invested USD65 million in SV Health Investors’s USD265 million fund, SV7 Impact Medicine Fund (IMF), which is dedicated to investing in biotech companies. Read full article
16 July 2020 – Three companies at Oxford’s BioEscalator are developing new detection methods and have discovered potential therapeutics in the fight against COVID-19. Even before the lockdown began, Nucleome Therapeutics, Alchemab Therapeutics and Hutano Diagnostics all quickly redirected their scientific expertise and business plans. These rapid innovations were achieved through collaborations with nearby experts, […]